Taken together, for the first time we showed that the concept of dose escalation of tamoxifen in CYP2D6 compromised breast cancer patients is feasible in an Iranian population resulting in significantly higher plasma concentrations of the active metabolite (Z)-endoxifen. The gene discussed is CYP2D6; the disease is breast cancer.